| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Clinical Strategies | EVP, Clinical Strategies
1 company
Kelli Mari Howell last filed a Form 4 in August 2022, as EVP, Clinical Strategies at ATEC. Kelli Mari Howell's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 540,098 shares of ATEC. Net of sales, the ATEC filings show accumulation of 100,000 shares.
Kelli Mari Howell has 13 Form 4 filings on record from March 2018 to August 2022, all as EVP, Clinical Strategies at Alphatec (ATEC), 2018–2022.
The 17 reported transactions were 9 stock awards, 5 tax withholdings, 2 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $259K and no sales.
The only open-market purchase was 100,000 shares of ATEC at an average $2.59 on March 11, 2019, about $259K.
Shares as reported in the last Form 4 for each company; the most recent is from August 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 11, 2019 | ATEC Alphatec Holdings, Inc. | EVP, Clinical Strategies | Buy | 100,000 | $2.59 | $258,930.00 | +94.7% |